HDFC Securities cites certain reasons for the positive approach towards IPCA Labs. They are as follows - strong volume growth in domestic formulation across therapeutic areas, cost-competitive and consistent quality driving better business prospects in API segment, robust debt-free B/S and strong return ratios and better traction in the international markets such as Europe and Asia. Source: ipca.com